PF-Atlas › Clinical Trials › NCT02460588
Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Cyclophosphamide · Phase 3
Registry ID
NCT02460588
Phase
Phase 3
Status
Completed
Drug / intervention
Cyclophosphamide
Sponsor
Assistance Publique - Hôpitaux de Paris
Start
2015-12
Enrollment
120
Locations
1
About this trial
Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a major event of IPF with an annual incidence between 5 and 10% and is responsible for the death of one third of IPF patients. When AE-IPF occurs, it is associated with poor survival with an overall mortality at 3 months upper of 50%. To date, no treatment has been proved to be effective in AE-IPF but the efficacy of cyclophosphamide (CYC) on survival has been suggested, mainly by retrospective series and needs to be confirmed. This confirmation is mandatory to improve prognosis of AE-IPF but also to avoid unsuspected deleterious effect as it as been shown with immunosuppressor in stable IPF.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT02460588 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.